Artificial intelligence news.
Straight from the original announcements.

Ozelle to show AI-assisted O-Cyte 1 hematology analyzer at MEDICA 2026

October 28, 2026, 09:15By the AI News Bites Editorial TeamSource: PR Newswire
Ozelle to show AI-assisted O-Cyte 1 hematology analyzer at MEDICA 2026
Image: PR Newswire

Ozelle will present O-Cyte 1 at MEDICA 2026 in Düsseldorf, an automated hematology analyzer that combines a complete blood count (CBC) with AI-assisted cell morphology and high-resolution cell images. According to the company, the system scales from 60 to 360 tests per hour and is designed for easier maintenance and servicing.

Key points
  • Ozelle will present the O-Cyte 1 AI-assisted hematology analyzer at MEDICA 2026 in Düsseldorf, 16 to 19 November.
  • O-Cyte 1 runs CBC tests with 7-subpopulation white blood cell differentiation and links high-resolution cell images to numerical results.
  • A standalone unit handles up to 60 tests per hour, and a six-unit cascade reaches up to 360 tests per hour, according to Ozelle.
  • Ozelle will also show the EHBT-75, the EHBT-50 and its AI-based Open Dx platform at Hall 1, stand D63.

What O-Cyte 1 does

According to Ozelle, O-Cyte 1 performs CBC tests with white blood cell differentiation into 7 subpopulations. High-resolution cell imaging and AI-assisted classification are integrated in a single analyzer. The company describes the system as combining AI with CBM, which stands for complete blood morphology.

The cell images are linked to the numerical results. Laboratory professionals can therefore look at the visual evidence when they need to, rather than relying only on automated classification. Ozelle says this reflects its vision for the fourth generation of hematology analysis: making morphological intelligence more consistent, reviewable and scalable within routine hematology workflows.

The company frames the product against a broader trend. As AI-assisted morphology becomes part of routine hematology, laboratories need more than automated cell classification, according to the announcement. Images must be available for professional review, and analyzers must also meet daily demands for sample throughput and maintenance.

Throughput and serviceability

Ozelle says O-Cyte 1 is built to handle varying workloads and routine service needs. A standalone analyzer runs up to 60 tests per hour, while a cascade configuration of six units reaches up to 360 tests per hour.

On the maintenance side, the company points to several design choices:

  • An integrated reagent kit, with key fluid-contact components housed in the consumables, which it says eases reagent handling and reduces routine maintenance.
  • Built-in self-verification systems.
  • Replaceable modules, which Ozelle says simplify fault identification and maintenance tasks.

The announcement also speaks directly to distributors of in vitro diagnostic (IVD) products. Scalable configurations make it easier to serve laboratories with different test volumes and offer a way to expand capacity later, according to the company. Simplified reagent management and a modular design may also make ongoing technical support and after-sales service easier.

Standards context and the rest of the MEDICA lineup

The release notes that the International Council for Standardization in Haematology (ICSH) approved a new digital morphology standardization project at its General Assembly on 14 and 15 October. According to the announcement, the initiative underlines the importance of verification, reproducibility and quality assurance in digital morphology.

Alongside O-Cyte 1, Ozelle will show two other systems. The EHBT-75 combines a 7-population hematology analysis with imaging and morphological analysis. The EHBT-50 integrates hematology, immunoassay and dry chemistry in one compact platform. Visitors can also see Open Dx, Ozelle's AI-based workspace platform, which is designed to support report review and result sharing using AI.

Ozelle will be at MEDICA 2026 from 16 to 19 November, in Hall 1, stand D63, at Messe Düsseldorf, where it invites visitors to try the systems and discuss distribution opportunities. The company says it was founded in Silicon Valley in 2014 and develops AI-based hematology and integrated diagnostic systems for both human and veterinary care.

What it means for laboratories and distributors

The pitch is aimed at two audiences. For laboratories, the key point is keeping cell images tied to numerical results, so staff can verify what the AI classified. For distributors, it is a platform that can be offered to customers with different volumes and expanded as their needs grow. All performance and maintenance claims come from Ozelle itself, and the announcement does not include independent test data.

OzelleO-Cyte 1MEDICA 2026International Council for Standardization in Hematologyhealthcareenterprise AI

Related news

Ozelle unveils O-Cyte 1 with built-in cell imaging at MEDICA 2026
Products and toolsNovember 16, 2026, 10:45

Ozelle unveils O-Cyte 1 with built-in cell imaging at MEDICA 2026

Ozelle is showcasing O-Cyte 1, an automated hematology analyzer that adds high-resolution cell imaging and AI-assisted morphology analysis to routine complete blood…

Ozelle demonstrates O-Cyte 1 automated cell imaging analyzer at MEDICA
Products and toolsNovember 16, 2026, 10:45

Ozelle demonstrates O-Cyte 1 automated cell imaging analyzer at MEDICA

Ozelle is demonstrating O-Cyte 1 at MEDICA 2026, an automated hematology analyzer that combines routine complete blood count testing with high-resolution cell imaging.…

Wincomm and Portwell to showcase medical AI systems at MEDICA 2026
Chips and infrastructureNovember 4, 2026, 18:21

Wincomm and Portwell to showcase medical AI systems at MEDICA 2026

Wincomm and Portwell will present a portfolio of medical computing platforms for mobile care, clinical AI and operating rooms at MEDICA 2026. The joint exhibition will…